Books and Book Chapters

      A Systems Toxicology Approach to Investigating the Cardiovascular Effects of Cigarette Smoke and Environmental Pollutants in ApoE-Deficient Mice

      De León, H.; Boue, S.; Peitsch, M. C.; Hoeng, J.

      Date published
      Sep 10, 2015
      DOI
      10.1007/978-1-4939-2778-4_14
      ISBN
      978-1-4939-2778-4
      Published in
      Computational Systems Toxicology
      Editors
      Hoeng, J.; Peitsch, M. C.
      Link to publication
      Topic
      Summary

      Epidemiological evidence indicates that exposure to combustion-derived particles is linked to an increased risk of cardiovascular disease. Despite this strong association, there remains a lack of data that can be used to identify the molecular mechanisms through which exposure to particulate matter (PM) leads to adverse cardiovascular events. The biological complexity of the responses generated by exposure to PM is compounded by the inherent multidimensional nature of the chemical mixtures associated with PM emitted from a range of sources, including diesel and gasoline exhausts, cigarette smoke, and ambient particles. The current challenges in this field of toxicology include the development and adoption of standardized in vitro and in vivo methods for testing multiple types of PM as individual entities or as mixtures. In this chapter, we focused on studies that have been published on the effects of combustion-derived PM in the ApoE-deficient mouse, a model of atherosclerosis that has proven to be a powerful in vivo surrogate for vascular disease in humans. A number of studies have been conducted in which the effects of diesel and gasoline exhausts, cigarette smoke, and concentrated ambient particles have been investigated, however, the exposure times, routes of PM delivery, and end points used in those studies have varied widely, making it challenging to compare the results of the studies. Despite these limitations, a few key findings on the development of vascular lesions in ApoE −/− mice can consistently be extracted from the published data. Future efforts should be aimed at systematizing the experimental designs and functional and molecular end points in studies using ApoE −/− mice so that the effects of different sizes and types of PM can be compared reliably. Functional end points and molecular data generated using ‘omics’ approaches, in which the transcriptome, lipidome, and proteome of ApoE −/− mice exposed to a diverse range of PM sources are examined, will be invaluable components in a systems biology approach to achieving a full understanding of the underlying biology of exposure to combustion-derived PM.

      Related Publications

      Tobacco Heating System 2.4 has less harmful impact on 2D bone co-culture system than cigarette smoke

      Pre-clinical Toxicology

      Characterizing the Genotoxic Potential of E-Cigarette Components In Vitro

      Pre-clinical Toxicology

      Evaluation of Chronic Toxicity and Carcinogenicity of Flavored E-Vapor Aerosols in an 18-Month Inhalation Study in A/J Mice

      Pre-clinical Toxicology

      Toxicological Assessment of Highly Mentholated Reduced-Risk Tobacco Products in Sprague Dawley Rats Following Sub-Chronic Inhalation Exposure

      Pre-clinical Toxicology

      Exposure to a Heated Tobacco Product Aerosol Is Associated with Lower Activity of Hepatic Cytochrome P450 Enzymes and Reduced Alteration in Clozapine Metabolism Than Exposure to Cigarette Smoke

      Pre-clinical Toxicology

      Evaluation of Chronic Inhalation Toxicity of E-Vapor Aerosols in an 18-Month Study in AJ Mice

      Pre-clinical Toxicology

      PMIScience.com is operated by Philip Morris International for the purpose of publishing and disseminating scientific information about Philip Morris International’s efforts in support of its smoke-free product portfolio. This site is a global site for use by scientists, the public health and regulatory communities, and other stakeholders with an interest in tobacco policy. The purpose of this site is not advertising or marketing, nor is it directed at any specific market. It is not intended for use by consumers. New tobacco products sold in the United States are subject to FDA regulation; therefore the content of this site is not intended to make, and nor should it be construed as making, any product related claims in the United States without proper FDA authorization. ​
      ​
      Reduced Risk Products ("RRPs”) is the term we use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continuing smoking. PMI has a range of RRPs in various stages of development, scientific assessment and commercialization. All of our RRPs are smoke-free products that deliver nicotine with far lower quantities of harmful and potentially harmful constituents than found in cigarette smoke.